Regeneron Pharmaceuticals (NASDAQ:REGN) closed out 2025 with what executives described as another “solid quarter of ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Regeneron beat Q4 earnings and sales estimates as Dupixent gains offset weaker Eylea sales. The drugmaker also outlined 2026 ...

CEO Leonard Schleifer reported "double-digit net sales growth for 3 of our leading products," highlighting a 26% increase in Dupixent, 24% for Libtayo at constant exchange rates, and a 10% increase ...

Regeneron Pharmaceuticals (NASDAQ:REGN) has inked a $3B deal with contract drug developer FUJIFILM Diosynth Biotechnologies (OTCPK:FUJIY) to boost production of its biologic medicines. The ...

Regeneron (REGN) stock in focus as the company posts Q4 2025 beat as its revenue tied to Sanofi (SNY) partnership offsets headwinds to Eylea franchise. Read more here.

SARATOGA SPRINGS, N.Y. — Gov. Kathy Hochul recently announced that Regeneron Pharmaceuticals, a global leader in biotechnology founded in New York State, will create 1,000 new jobs as part of a $2 ...

Chautauqua Capital Management, a division of Baird Asset Management, is a boutique investment firm that released its ...

Tarrytown-based pharmaceutical company Regeneron has reported revenues for 2025 of $14.3 billion, an increase of 1% over the revenues for ...

Regeneron is expanding its pharmaceutical production in New York, joining a wave of drug companies growing domestic manufacturing in the wake of President Donald Trump’s tariffs. The move is a boon to ...

Nov 17 (Reuters) - Roche Holding AG (ROG.S), opens new tab has completed early tests of its ability to produce large quantities of Regeneron Pharmaceuticals Inc's (REGN.O), opens new tab COVID-19 ...

FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo (Reuters) -The U.S. Food and ...